Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Updates from the ECHELON-1 study

David Straus • 18 Aug 2020
SOHO 2020
Hodgkin Lymphoma Lymphoma Antibodies Bleomycin Brentuximab vedotin Dacarbazine Doxorubicin Nivolumab Vinblastine

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, updates us on long term results of the ECHELON-1 study (NCT01712490), evaluating brentuximab vedotin, an antibody-drug conjugate, with chemotherapy for stage III/IV classical Hodgkin lymphoma. Furthermore, Dr Straus elaborates on an ongoing study evaluating BV + ABD against nivolumab + ABD. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Straus

6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
8:50
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
David Straus • 2 Dec 2020
2:34
R/R lymphoma: checkpoint blockade and transplantation
David Straus • 18 Aug 2020
3:24
Treatment of bulky stage I/II lymphoma
David Straus • 18 Aug 2020

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024
1:24
Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi • 24 Apr 2024
The content of VJHemOnc is intended for healthcare professionals